Third-Generation Anti-Cd19 Chimeric Antigen Receptor T-Cells Incorporating a TLR2 Domain for Relapsed or Refractory B-Cell Lymphoma: A Phase I Clinical Trial Protocol (ENABLE)
BMJ Open - United Kingdom
doi 10.1136/bmjopen-2019-034629
Full Text
Open PDFAbstract
Available in full text
Categories
Date
February 1, 2020
Authors
Publisher
BMJ